Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences

Executive Summary

Merck adds to its stagnating HIV portfolio with US approvals of doravirine and a three-drug combo including the NNRTI, but the combo’s potential may be limited due to inclusion of an older version of tenofovir.

Advertisement

Related Content

Keytruda Is King, But Merck Faces Questions About Business Development
Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown
Keeping Track: Busy August Ends With Approval For Doravirine, CRLs For Dasotraline And Waylivra
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel